Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Return on Equity (2017 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Return on Equity for 11 consecutive years, with 1.14% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 60.0% to 1.14% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.14% through Dec 2025, down 60.0% year-over-year, with the annual reading at 0.56% for FY2025, 9.0% down from the prior year.
  • Return on Equity hit 1.14% in Q4 2025 for Vistagen Therapeutics, down from 1.01% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.19% in Q1 2021 to a low of 4.9% in Q2 2023.
  • Historically, Return on Equity has averaged 1.15% across 5 years, with a median of 0.67% in 2022.
  • Biggest five-year swings in Return on Equity: crashed -2292bps in 2021 and later soared 460bps in 2024.
  • Year by year, Return on Equity stood at 0.46% in 2021, then crashed by -446bps to 2.53% in 2022, then surged by 84bps to 0.4% in 2023, then tumbled by -35bps to 0.54% in 2024, then tumbled by -110bps to 1.14% in 2025.
  • Business Quant data shows Return on Equity for VTGN at 1.14% in Q4 2025, 1.01% in Q3 2025, and 0.88% in Q2 2025.